• Research and Development

    Shaping the
    future of medicine
    Start »

09/14/15, Research and Development Bayer to Present Data from Oncology Portfolio at ECC2015 in Vienna Additional analyses of regorafenib from the Phase III CONCUR and Phase IIIb CONSIGN clinical trials in metastatic colorectal cancer / Clinical data presentation of Bayer’s CDK inhibitor roniciclib (BAY-1000394) in patients with extensive disease small cell lung cancer / Additional results from Phase III ALSYMPCA trial and U.S. expanded access program of radium-223 dichloride in metastatic castration-resistant prostate cancer more

08/27/15, Research and Development Bayer to Present Latest Clinical Data on Finerenone in Hot Line Session at ESC ARTS-HF-Phase IIb-study results of finerenone in patients with worsening chronic heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus and/or chronic kidney disease more

At a glance


Research expenses 2014 EUR 1,878 million
In percent of division sales 2014
Main research sites Berlin and Wuppertal, Germany and Berkeley, USA
Research focus
  • Berlin:
    oncology, women's healthcare
  • Wuppertal:
    Cardiology, oncology
  • Berkeley:
    Applied research and life cycle management in hemophilia and multiple sclerosis


Image: Research and Development

Promising pipeline ensures mid- and long-term innovation

Bayer HealthCare Pharmaceuticals concentrates its R&D activities on innovative treatment alternatives for diseases with a high unmet medical need to improve patients’ quality of life and prolong lives. The focus is on therapeutic areas with a high medical need, where more innovations are needed despite considerable progress.

We hold a leading position in many therapeutic fields: for instance in the treatment of hemophilia and multiple sclerosis, in contrast media and oral contraception. We are also striving for such a leading position in oncology.

Image: Clinical trials

About Clinical Trials

Clinical trials are used to evaluate potential treatments that have had some effect against disease in the lab, or in animal experiments. The whole point of a clinical trial is to find out if a treatment is effective.

Until sufficient results are available from many different trials it is just that, potential. Effectiveness of a treatment should never be at the expense of safety; the benefit of a treatment should always outweigh the harm and is fundamental to the conduct of all clinical trials.

Page tools
Interactive tool
Grants for Targets
Clinical Trials


Copyright © Bayer Pharma AG